tiprankstipranks
Vertex Pharmaceuticals Inc. (VRTX)
NASDAQ:VRTX
US Market
VRTX
Vertex Pharmaceuticals
RESEARCH TOOLSreports
Want to see VRTX full AI Analyst Report?

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

6,765 Followers
See the Price Targets and Ratings of:

VRTX Analyst Ratings

Strong Buy
25Ratings
Strong Buy
20 Buy
4 Hold
1 Sell
Based on 25 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$559.27
▲(17.16% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $559.27 with a high forecast of $653.00 and a low forecast of $350.00. The average price target represents a 17.16% change from the last price of $477.36.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"349":"$349","654":"$654","425.25":"$425.3","501.5":"$501.5","577.75":"$577.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":653,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$653.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":559.2727272727273,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$559.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$350.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[349,425.25,501.5,577.75,654],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,477.1,490.63076923076926,504.1615384615385,517.6923076923077,531.223076923077,544.7538461538462,558.2846153846153,571.8153846153846,585.3461538461538,598.876923076923,612.4076923076923,625.9384615384615,639.4692307692308,{"y":653,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,477.1,483.420979020979,489.74195804195807,496.06293706293707,502.3839160839161,508.7048951048951,515.0258741258741,521.3468531468532,527.6678321678322,533.9888111888112,540.3097902097902,546.6307692307693,552.9517482517482,{"y":559.2727272727273,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,477.1,467.32307692307694,457.54615384615386,447.7692307692308,437.9923076923077,428.2153846153846,418.4384615384615,408.6615384615385,398.88461538461536,389.10769230769233,379.3307692307692,369.55384615384617,359.7769230769231,{"y":350,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":462.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":453.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":472.01,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":486.03,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447.26,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":423.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":438.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.01,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":477.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$653.00Average Price Target$559.27Lowest Price Target$350.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on VRTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$66→$500
Hold
4.74%
Upside
Reiterated
08/09/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Truist Financial Analyst forecast on VRTX
Danielle Brill
Truist Financial
Truist Financial
$560→$565
Buy
18.36%
Upside
Assigned
08/05/26
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (NYSE: AMN), Fresenius Medical Care (NYSE: FMS) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Barclays Analyst forecast on VRTX
Eliana Merle
Barclays
Barclays
$615→$617
Buy
29.25%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on VRTX
Naz Rahman
Maxim Group
Maxim Group
$575
Buy
20.45%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Q32 Bio (NASDAQ: QTTB)
William Blair Analyst forecast on VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analysts' Top Healthcare Picks: Danaher (DHR), Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Analyst forecast on VRTX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$641
Buy
34.28%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Evercore ISI Analyst forecast on VRTX
Cory Kasimov
Evercore ISI
Evercore ISI
$535
Buy
12.07%
Upside
Reiterated
08/04/26
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Needham Analyst forecast on VRTX
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
08/04/26
Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
Canaccord Genuity Analyst forecast on VRTX
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$436→$442
Hold
-7.41%
Downside
Reiterated
08/04/26
Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
Wells Fargo Analyst forecast on VRTX
Mohit Bansal
Wells Fargo
Wells Fargo
$540→$550
Buy
15.22%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
Goldman Sachs Analyst forecast on VRTX
Salveen Richter
Goldman Sachs
Goldman Sachs
$652→$653
Buy
36.79%
Upside
Assigned
08/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alphatec Holdings (NASDAQ: ATEC), Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
TD Cowen Analyst forecast on VRTX
Phil Nadeau
TD Cowen
TD Cowen
$525→$550
Buy
15.22%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from TD Cowen
Scotiabank Analyst forecast on VRTX
Louise Chen
Scotiabank
Scotiabank
$558
Buy
16.89%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Scotiabank
Cantor Fitzgerald Analyst forecast on VRTX
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$590→$595
Buy
24.64%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Stoke Therapeutics (NASDAQ: STOK) and SI-Bone (NASDAQ: SIBN)
UBS Analyst forecast on VRTX
Michael Yee
UBS
UBS
$585
Buy
22.55%
Upside
Reiterated
08/04/26
Vertex: Buy Rating Reaffirmed with Unchanged $585 Price Target on Strong CF Performance and Late-Stage Pipeline Upside
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on VRTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$66→$500
Hold
4.74%
Upside
Reiterated
08/09/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Truist Financial Analyst forecast on VRTX
Danielle Brill
Truist Financial
Truist Financial
$560→$565
Buy
18.36%
Upside
Assigned
08/05/26
Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (NYSE: AMN), Fresenius Medical Care (NYSE: FMS) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Barclays Analyst forecast on VRTX
Eliana Merle
Barclays
Barclays
$615→$617
Buy
29.25%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on VRTX
Naz Rahman
Maxim Group
Maxim Group
$575
Buy
20.45%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Q32 Bio (NASDAQ: QTTB)
William Blair Analyst forecast on VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/04/26
Analysts' Top Healthcare Picks: Danaher (DHR), Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Analyst forecast on VRTX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$641
Buy
34.28%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Evercore ISI Analyst forecast on VRTX
Cory Kasimov
Evercore ISI
Evercore ISI
$535
Buy
12.07%
Upside
Reiterated
08/04/26
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Needham Analyst forecast on VRTX
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
08/04/26
Vertex Pharmaceuticals: Solid Q2 Beat and Raised 2026 Guidance, But Early-Stage Diversification and CRNX Integration Keep Rating at Hold
Canaccord Genuity Analyst forecast on VRTX
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$436→$442
Hold
-7.41%
Downside
Reiterated
08/04/26
Vertex: Solid CF Fundamentals and Early Pipeline Credit Drive Price Target Raise to $442, Hold Rating Maintained
Wells Fargo Analyst forecast on VRTX
Mohit Bansal
Wells Fargo
Wells Fargo
$540→$550
Buy
15.22%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
Goldman Sachs Analyst forecast on VRTX
Salveen Richter
Goldman Sachs
Goldman Sachs
$652→$653
Buy
36.79%
Upside
Assigned
08/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alphatec Holdings (NASDAQ: ATEC), Amgen (NASDAQ: AMGN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
TD Cowen Analyst forecast on VRTX
Phil Nadeau
TD Cowen
TD Cowen
$525→$550
Buy
15.22%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from TD Cowen
Scotiabank Analyst forecast on VRTX
Louise Chen
Scotiabank
Scotiabank
$558
Buy
16.89%
Upside
Assigned
08/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Scotiabank
Cantor Fitzgerald Analyst forecast on VRTX
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
$590→$595
Buy
24.64%
Upside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Stoke Therapeutics (NASDAQ: STOK) and SI-Bone (NASDAQ: SIBN)
UBS Analyst forecast on VRTX
Michael Yee
UBS
UBS
$585
Buy
22.55%
Upside
Reiterated
08/04/26
Vertex: Buy Rating Reaffirmed with Unchanged $585 Price Target on Strong CF Performance and Late-Stage Pipeline Upside
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
Mohit BansalWells Fargo
Success Rate
25/34 ratings generated profit
74%
Average Return
+7.25%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 73.53% of your transactions generating a profit, with an average return of +7.25% per trade.
1 Year
Salveen RichterGoldman Sachs
Success Rate
18/23 ratings generated profit
78%
Average Return
+10.84%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 78.26% of your transactions generating a profit, with an average return of +10.84% per trade.
2 Years
Michael YeeUBS
Success Rate
28/30 ratings generated profit
93%
Average Return
+20.07%
Copying Michael Yee's trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +20.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
45
42
33
50
49
Hold
13
11
9
9
9
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
58
53
42
60
59
In the current month, VRTX has received 49 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. VRTX average Analyst price target in the past 3 months is 559.27.
Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $4.79 with a range of $3.68 to $5.18. The previous quarter’s EPS was $4.73. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 44.90% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for VRTX is $4.79 with a range of $3.68 to $5.18. The previous quarter’s EPS was $4.73. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 44.90% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $3.40B with a range of $3.33B to $3.50B. The previous quarter’s sales results were $3.34B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 59.72% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.
Next quarter’s sales forecast for VRTX is $3.40B with a range of $3.33B to $3.50B. The previous quarter’s sales results were $3.34B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 59.72% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals Inc.’s 12-month average price target is 559.27.
    What is VRTX’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals Inc. has 17.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VRTX a Buy, Sell or Hold?
          Vertex Pharmaceuticals Inc. has a consensus rating of Strong Buy which is based on 20 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Vertex Pharmaceuticals Inc.’s price target?
            The average price target for Vertex Pharmaceuticals Inc. is 559.27. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $653.00 ,the lowest forecast is $350.00. The average price target represents 17.16% Increase from the current price of $477.36.
              What do analysts say about Vertex Pharmaceuticals Inc.?
              Vertex Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of VRTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.